|
n
|
31,495
|
35,507
|
1790
| |
|
Age (mean (SD))
|
62.47 (5.27)
|
62.93 (6.80)
|
58.68 (9.63)
|
0.35
|
|
African American = yes (%)
|
1279 (4.1)
|
5256 (14.8)
|
173 (9.7)
|
0.25
|
|
BMI (mean (SD))
|
27.61 (4.19)
|
28.59 (4.60)
|
28.17 (4.80)
|
0.15
|
|
Family history of cancer = yes (%)
|
2299 (7.4)
|
5929 (16.7)
|
424 (23.7)
|
0.31
|
|
Cancer diagnosis = yes (%)
|
2798 (8.9)
|
2550 (7.2)
|
198 (11.1)
|
0.09
|
|
Cancer grade (%)
| | | |
0.28
|
|
Low-grade cancer
|
935 (33)
|
1756 (69)
|
169 (85)
| |
|
High-grade cancer (Gleason > 7)
|
375 (13)
|
146 (6)
|
22 (11)
| |
|
Missing grade
|
1488 (53)
|
648 (25)
|
7 (4)
| |
|
DRE = suspicious (%)
|
2082 (6.6)
|
3 (0.0)
|
295 (16.5)
|
0.44
|
|
BPH = yes (%)
|
6463 (20.6)
|
5334 (15.0)
|
626 (35.0)
|
0.31
|
|
Baseline PSA (mean (SD))
|
1.30 (0.88)
|
1.35 (0.94)
|
1.16 (0.79)
|
0.15
|
|
Follow-up years (median (IQR])
|
11.7 [9.6, 12.9]
|
8.1 [6.1, 10.3]
|
9.02 [4.76, 13.16]
|
0.54
|
|
PCa follow-up (median (IQR])
|
6.7 [3.5, 9.5]
|
4.2[2.3, 6.0]
|
5.62 [3.17, 8.32]
|
0.49
|
|
No PCa follow-up (median (IQR])
|
12.5 [10.5, 12.9]
|
8.4[6.5, 10.4]
|
9.74 [5.28, 13.44]
|
0.60
|
